Spectral Diagnostics Inc. has announced that its common shares have commenced trading on OTCQX International, the highest tier of the OTC market in the United States, under the symbol "DIAGF".
Spectral's common shares will continue to trade on the TSX under the symbol "SDI".
Spectral expects to benefit from trading on OTCQX by gaining greater exposure and liquidity in the United States, which represents the major market for its theranostic treatment, and where most of its Phase III EUPHRATES trial sites are located.
"We believe OTCQX will provide an expedient and transparent forum for investors in the United States, the world's largest equity market, to evaluate Spectral as a prospective investment and increase awareness of the Company's ongoing developments and progress," said Anthony Businskas, Executive Vice President and CFO of Spectral.
Brean Murray, Carret & Co. will act as the Company's Principal American Liaison (PAL) on OTCQX, and provide guidance on OTCQX requirements.